SCHEMBL4194865

SCHEMBL4194865

O=c1c2cncnc2nc(-c2ccc(F)cc2)n1NCc1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 13/20 0.49
CYP3A4 P08684 12/20 0.49
USP2 O75604 11/20 0.49
CYP2C9 P11712 8/20 0.49
MAPK1 P28482 6/20 0.49
HIF1A Q16665 3/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 5/20 0.39
HTT P42858 1/20 0.39
CYP2C19 P33261 7/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
KMT2A Q03164 2/20 0.39
ALOX15 P16050 2/20 0.39
TRPA1 O75762 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202613 0.85 SMN1; SMN2 (0.48) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4193513 0.82 SMN1; SMN2 (0.50) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4194181 0.80 ALDH1A1 (0.41) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4233295 0.79 SMN1; SMN2 (0.53) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4237651 0.79 SMN1; SMN2 (0.67) CYP1A2CYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL4357822 0.78 TRPA1 (0.40) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4194208 0.77 SMN1; SMN2 (0.46) CYP1A2CYP3A4USP2CYP2C9MAPK1
SCHEMBL4233197 0.76 SMN1; SMN2 (0.48) CYP1A2CYP3A4CYP2C9SMN1; SMN2ALDH1A1
SCHEMBL4239826 0.76 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1HTTMEN1KMT2A
SCHEMBL4237411 0.76 SMN1; SMN2 (0.54) MAPK1SMN1; SMN2ALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 CYP1A2 2694/4885CYP3A4 2487/4885USP2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.